Esperion to Participate in Upcoming June Investor Conferences
Esperion (NASDAQ: ESPR) has announced its participation in two major investor conferences in June 2025: the Jefferies Global Healthcare Conference in New York on June 4 at 1:25 p.m. ET, and the Goldman Sachs Global Healthcare Conference in Miami on June 9 at 10:40 a.m. ET.
The company, a commercial stage biopharmaceutical firm, specializes in FDA-approved oral, once-daily, non-statin medicines for patients with cardiovascular disease and elevated LDL-C. Their medications are supported by the CLEAR Cardiovascular Outcomes Trial involving nearly 14,000 patients. Esperion is also developing next-generation ATP citrate lyase inhibitors (ACLYi) and expanding globally through commercial execution and international partnerships.
Esperion (NASDAQ: ESPR) ha annunciato la sua partecipazione a due importanti conferenze per investitori nel giugno 2025: la Jefferies Global Healthcare Conference a New York il 4 giugno alle 13:25 ET e la Goldman Sachs Global Healthcare Conference a Miami il 9 giugno alle 10:40 ET.
L'azienda, una società biofarmaceutica in fase commerciale, è specializzata in farmaci orali approvati dalla FDA, da assumere una volta al giorno, non statine, destinati a pazienti con malattie cardiovascolari e livelli elevati di LDL-C. I loro farmaci sono supportati dallo studio CLEAR Cardiovascular Outcomes Trial, che ha coinvolto quasi 14.000 pazienti. Esperion sta inoltre sviluppando inibitori di nuova generazione dell'ATP citrato liasi (ACLYi) e sta espandendo la propria presenza a livello globale attraverso l'esecuzione commerciale e partnership internazionali.
Esperion (NASDAQ: ESPR) ha anunciado su participación en dos importantes conferencias para inversores en junio de 2025: la Jefferies Global Healthcare Conference en Nueva York el 4 de junio a la 1:25 p.m. ET, y la Goldman Sachs Global Healthcare Conference en Miami el 9 de junio a las 10:40 a.m. ET.
La compañía, una firma biofarmacéutica en etapa comercial, se especializa en medicamentos orales aprobados por la FDA, de una vez al día, no estatinas, para pacientes con enfermedades cardiovasculares y niveles elevados de LDL-C. Sus medicamentos están respaldados por el ensayo CLEAR Cardiovascular Outcomes Trial, que involucró a casi 14,000 pacientes. Esperion también está desarrollando inhibidores de la ATP citrato liasa (ACLYi) de próxima generación y expandiéndose globalmente a través de la ejecución comercial y asociaciones internacionales.
에스페리온 (NASDAQ: ESPR)은 2025년 6월 두 개의 주요 투자자 컨퍼런스에 참가할 예정임을 발표했습니다: 6월 4일 뉴욕에서 열리는 Jefferies Global Healthcare Conference 오후 1시 25분(동부시간), 그리고 6월 9일 마이애미에서 열리는 Goldman Sachs Global Healthcare Conference 오전 10시 40분(동부시간)입니다.
이 회사는 상업 단계의 생명공학 제약 회사로, 심혈관 질환과 높은 LDL-C 수치를 가진 환자들을 위한 FDA 승인 구강용 비스타틴제(하루 1회 복용)를 전문으로 합니다. 이들의 약물은 약 14,000명의 환자가 참여한 CLEAR 심혈관 결과 시험에 의해 뒷받침됩니다. 에스페리온은 또한 차세대 ATP 시트르산 분해효소 억제제(ACLYi)를 개발 중이며, 상업적 실행과 국제 파트너십을 통해 글로벌 확장을 추진하고 있습니다.
Esperion (NASDAQ : ESPR) a annoncé sa participation à deux grandes conférences pour investisseurs en juin 2025 : la Jefferies Global Healthcare Conference à New York le 4 juin à 13h25 ET, et la Goldman Sachs Global Healthcare Conference à Miami le 9 juin à 10h40 ET.
La société, une entreprise biopharmaceutique en phase commerciale, se spécialise dans les médicaments oraux non-statines approuvés par la FDA, à prise quotidienne unique, destinés aux patients atteints de maladies cardiovasculaires et présentant un taux élevé de LDL-C. Leurs médicaments sont soutenus par l'essai CLEAR Cardiovascular Outcomes Trial impliquant près de 14 000 patients. Esperion développe également des inhibiteurs de nouvelle génération de l'ATP citrate lyase (ACLYi) et étend sa présence mondiale grâce à une exécution commerciale et des partenariats internationaux.
Esperion (NASDAQ: ESPR) hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im Juni 2025 angekündigt: der Jefferies Global Healthcare Conference in New York am 4. Juni um 13:25 Uhr ET und der Goldman Sachs Global Healthcare Conference in Miami am 9. Juni um 10:40 Uhr ET.
Das Unternehmen, ein biopharmazeutisches Unternehmen in der kommerziellen Phase, spezialisiert sich auf von der FDA zugelassene orale, einmal täglich einzunehmende Nicht-Statin-Medikamente für Patienten mit Herz-Kreislauf-Erkrankungen und erhöhtem LDL-C. Ihre Medikamente werden durch die CLEAR Cardiovascular Outcomes Trial gestützt, an der fast 14.000 Patienten teilnahmen. Esperion entwickelt außerdem die nächste Generation von ATP-Citrat-Lyase-Inhibitoren (ACLYi) und expandiert global durch kommerzielle Umsetzung und internationale Partnerschaften.
- None.
- None.
ANN ARBOR, Mich., May 20, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following webcasted investor events during the month of June, which can be found on our investor relations website.
Jefferies Global Healthcare Conference in New York on June 4, 2025, at 1:25 p.m. ET.
Goldman Sachs Global Healthcare Conference in Miami on June 9, 2025, at 10:40 a.m. ET.
Live webcasts can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days.
Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms.
Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit esperion.com and follow Esperion on LinkedIn and X.
Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903
Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438
FAQ
What investor conferences will Esperion (ESPR) attend in June 2025?
How can investors access Esperion's (ESPR) conference presentations?
What are Esperion's (ESPR) main pharmaceutical products?
What is Esperion's (ESPR) next-generation drug development program?
